Home/Pipeline/DiviTum® TKa

DiviTum® TKa

Monitoring metastatic breast cancer (on CDK4/6 inhibitors)

CommercialFDA 510(k) Cleared, CE-Marked

Key Facts

Indication
Monitoring metastatic breast cancer (on CDK4/6 inhibitors)
Phase
Commercial
Status
FDA 510(k) Cleared, CE-Marked
Company

About Biovica

Founded in 2009, Biovica is dedicated to transforming cancer care management through innovative biomarker-based tests. Its core technology, the DiviTum® TKa test, has been validated in over 4,500 patients across 28 publications and is supported by 32 pharmaceutical projects. With regulatory clearances in the US and EU, and a CLIA-certified lab in San Diego, Biovica is positioned to enable more confident treatment decisions by providing early and sensitive monitoring of therapy efficacy.

View full company profile

About Biovica

Founded in 2009, Biovica is dedicated to transforming cancer care management through innovative biomarker-based tests. Its core technology, the DiviTum® TKa test, has been validated in over 4,500 patients across 28 publications and is supported by 32 pharmaceutical projects. With regulatory clearances in the US and EU, and a CLIA-certified lab in San Diego, Biovica is positioned to enable more confident treatment decisions by providing early and sensitive monitoring of therapy efficacy.

View full company profile

About Biovica

Founded in 2009, Biovica is dedicated to transforming cancer care management through innovative biomarker-based tests. Its core technology, the DiviTum® TKa test, has been validated in over 4,500 patients across 28 publications and is supported by 32 pharmaceutical projects. With regulatory clearances in the US and EU, and a CLIA-certified lab in San Diego, Biovica is positioned to enable more confident treatment decisions by providing early and sensitive monitoring of therapy efficacy.

View full company profile

About Biovica

Founded in 2009, Biovica is dedicated to transforming cancer care management through innovative biomarker-based tests. Its core technology, the DiviTum® TKa test, has been validated in over 4,500 patients across 28 publications and is supported by 32 pharmaceutical projects. With regulatory clearances in the US and EU, and a CLIA-certified lab in San Diego, Biovica is positioned to enable more confident treatment decisions by providing early and sensitive monitoring of therapy efficacy.

View full company profile

Therapeutic Areas